Zymeworks Inc. (ZYME) |
|
47.97 -0.29 (-0.6%)
|
02-14 16:02 |
|
Open: |
48.32 |
Pre. Close: |
48.26 |
|
High:
|
48.75 |
Low:
|
47.12 |
|
Volume:
|
122,954 |
Market Cap:
|
2182M |
|
|
|
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
48.795 - 49.032 |
49.032 - 49.236 |
|
Low:
|
46.669 - 46.94 |
46.94 - 47.173 |
|
Close:
|
47.851 - 48.274 |
48.274 - 48.64 |
|
Technical analysis |
as of: 2020-02-14 4:34:03 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 61.61 One year: 71.96 |
| Support: |
Support1: 42.28 Support2: 35.81 |
| Resistance: |
Resistance1: 52.75 Resistance2: 61.61 |
| Pivot: |
46.22  |
| Moving Average: |
MA(5): 48.42 MA(20): 46.62
MA(100): 38.89 MA(250): 27.80 |
| MACD: |
MACD(12,26): 0.90 Signal(9): 0.69 |
| Stochastic oscillator: |
%K(14,3): 82.38 %D(3): 75.28 |
| RSI: |
RSI(14): 56.74 |
| 52-week: |
High: 52.75 Low: 14.05 Change(%): 211.8 |
| Average Vol(K): |
3-Month: 44437 10-Days: 20819 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.ZYME has closed below upper band by 21.8%. Bollinger Bands are 10.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2020-01-23
The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT )(reported strong fourth-quarter results and issued in-line guidance) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) Bristol-Myers Squibb Co (NYSE: BMY ) Cardiovascular Systems Inc (NASDAQ: CSII ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Eli Lilly And Co (NYSE: LLY ) Fortress Biotech (NASDAQ: FBIO ) Horizon Therapeutics PLC (NASDAQ: HZNP )( received FDA nod for its thyroid eye disease drug) Insulet Corporation (NASDAQ: PODD ) Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR )(announced coverage in Israel for its Optune in combination with temozolomide for the treatment of newly-diagnosed glioblastoma) Prevail Therapeutics Inc (NASDAQ: PRVL ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Selecta Biosciences Inc (NASDAQ: SELB ) SI-Bone Inc (NASDAQ: SIBN ) Soligenix, Inc.
2020-01-13
Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities. Zymeworks also announced multiple clinical program advances for its lead candidates, ZW25 and ZW49. Recent ZW25 and ZW49 Program Advances Zymeworks initiated a Phase 2 clinical trial evaluating ZW25 in combination with Ibrance® (palbociclib), an ora
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
